insights_auto
Waarom is 6160 gestegen 4,36%?
Meer informatiechevron_right
6160:HKG
BeOne Medicines AG
HK$Â 225,00
arrow_upward
+4,36%(+9,40) 1D
16 okt, 16:08:14 GMT+8 · HKD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 6160 genereren…
Openen
HK$Â 224,80
Hoog
HK$Â 230,20
Laag
HK$Â 221,80
Beursw.
355,76Â mld.
Gem. vol.
2,93Â mln.
Volume
4,41Â mln.
Koers/winst-verhouding
65,67
52 wk hoog
HK$Â 235,60
52 wk laag
HK$Â 153,00
WPA
HK$Â 3,43
Uitstaande aandelen
1,43Â mld.
Aantal medewerkers
12K
Openen
HK$Â 224,80
Hoog
HK$Â 230,20
Laag
HK$Â 221,80
Beursw.
355,76Â mld.
Gem. vol.
2,93Â mln.
Volume
4,41Â mln.
Koers/winst-verhouding
65,67
52 wk hoog
HK$Â 235,60
52 wk laag
HK$Â 153,00
WPA
HK$Â 3,43
Uitstaande aandelen
1,43Â mld.
Aantal medewerkers
12K
Nieuwsartikelen
Van webbronnen en nieuwspartners
ad-hoc-news.de
·
1 dag geleden
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
MarketBeat
·
2 dagen geleden
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profiel
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Over BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Medewerkers12K
Opgericht28 okt 2010
Hoofdkantoor-
Sector-
Websitebeonemedicines.com